Drugs Patent Status – India

Lawyers Collective with support from UNITAID has created a searchable patent information status for key medicines in India. This is an effort to make available robust patent status information for key medicines with details on patent applications that are pending rejected and patented in India. This will add to the existing pool of publicly available data on the patent status for key medicines made available by initiatives of Medicines Patent Pool (http://www.medicinespatentpool.org/patent-data/patent-status-of-arvs/), I-MAK (http://essentialdrugpatents.com/ ) for various countries. Unlike other patent databases though the geographical scope is limited for Lawyers Collective Key Medicines Patent Status In India the purpose is to create an exhaustive and provide extensive information on all the patents granted and applications filed in India for key medicines. The Lawyers Collective patent status information will complement the existing patent databases.

The information available for each drug will provide details on regulatory approval, patent prosecution status such as issuance of first examination report by the patent office, any opposition filed against applications and the status of the application as displayed in the patent office website.

The information is collected from various publicly available and accessible databases including USFDA, EMEA, DCGI, USPTO, Espacenet, WIPO-Patentscope etc and details for applications filed in India is compiled from the Indian Patent Office website (IPAIRS http://ipindiaservices.gov.in/patentsearch/search/index.aspx ).

The information is presently limited to select set of drugs however we intend to include new drugs and expand the information on patent status of the key drugs in near future. Lawyers Collective will endeavor to update the information on the patent status and regulatory approvals in a timely manner.

Please note the regulatory approval information and patent status details made available in this database is only for information purpose and is sourced from publicly available and accessible websites. For further information on regulatory approval, recent status and development on particular drug and patent application we request you to approach the relevant authority.

Please do write to us if you have any queries, suggestions to improve the database and if you notice any inadequacies at [email protected] and [email protected] .

Lawyers Collective Patent Application Status Information

India is a major supplier of key drugs and pharmaceuticals to the world fish scale coke
. The country produces more than 40 percent of the world’s generic drugs, which are 60% cheaper than branded drugs in the developed world and often the only option for millions of poor patients in Africa and Asia

Drug Name
Generic Name (INN)
Brand Name Clinical Use Drug Class Regulatory Approval
Dolutegravir TIVICAY HIV Integrase Inhibitor USFDA, EMA
Raltegravir ISENTRESS HIV Integrase Inhibitor WHO-PQP, USFDA, EMA, DCGI
Elvitegravir VITEKTA HIV Integrase Inhibitor USFDA, EMA
Cobicistat TYBOST HIV Pharmacokinetic enhancer USFDA, EMA
Tenofovir Alafenamide Fumarate HIV Nucleotide Reverse Transcriptase Inhibitor
Lopinavir/Ritonavir KALETRA HIV Protease Inhibitor USFDA, EMA, DCGI
Nevirapine VIRAMUNE HIV Non-nucleoside Reverse Transcriptase Inhibitor USFDA, EMA, DCGI
Atazanavir REYATAZ HIV Protease Inhibitor USFDA, EMA
Tenofovir Disproxil Fumarate VIREAD HIV Nucleotide Analogue Reverse Transcriptase Inhibitor USFDA, EMA, DCGI
Abacavir /Dolutegravir /Lamivudine TRIMEQ HIV USFDA, EMA
Cabotegravir HIV Integrase Inhibitor
Darunavir/cobicistat REZOLSTA (EU)
HIV Protease Inhibitor EMA
Sofosbuvir SOVALDI HCV NS5B Polymerase Inhibitor USFDA, EMA, DCGI
Ledipasvir HCV NS5A Inhibitor
Simeprevir OLYSIO HCV NS3/4A Protease Inhibitor USFDA, EMA, PMDA
Sofosbuvir/Ledipasvir HARVONI HCV USFDA, EMA
Daclatasvir DAKLINZA HCV NS5A Inhibitor USFDA, EMA
Asunaprevir SUNVEPRA HCV NS3/4A Protease Inhibitor PMDA
Dasabuvir EXVIERA HCV Non-nucleoside Polymerase Inhibitor
Ombitasvir/Paritaprevir/Ritonavir VIEKIRAX HCV
Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir VIEKIRAX + EXVIERA HCV USFDA, EMA
Ombitasvir HCV NS5A Inhibitor
Paritaprevir HCV NS3/4A Protease Inhibitor
Velpatasvir HCV NS3/4A Protease Inhibitor
Grazoprevir HCV NS3/NA Protease Inhibitor
Elbasvir HCV NS5A Inhibitor
Bedaquiline SIRTURO TB Diarlyquinoline USFDA, EMA
Delamanid DELTYBA TB Nitro-dihydro-imidazooxazoles EMA
Sutezolid TB Oxazolinidinone